Project Grant R43CA281488
Award Date
8/1/23
Completion Date
7/31/24
Dollars Obligated
$530K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award, identified as R21CA291788, was provided by the National Cancer Institute (NCI) under the Federal Grant Program "Cancer Treatment Research" (CFDA 93.395). The $215,311 grant will fund research into developing antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key products and services to be delivered under this grant include: Generation and evaluation of GPR56-targeted ADCs with...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,001,029 to Immunova Therapeutics LLC to develop a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The key products to be delivered under this award include: Generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product. Determination of the pharmacokinetics, biodistribution, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to improve the treatment of advanced metastatic triple-negative breast cancer (TNBC). The $622,329 award to Virginia Commonwealth University will fund research to develop and test a novel small molecule inhibitor called PDZ1i that targets the MDA-9 protein to prevent metastasis and sensitize tumors to chemotherapy. Specifically, the research will focus on formulating PDZ1i for clinical...
The National Cancer Institute (NCI), under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $400,000 Project Grant to Promilead, LLC in South Carolina to conduct research on enhancing the efficacy of immunotherapy for triple-negative breast cancer (TNBC). The grant aims to evaluate the efficacy of a small-molecule compound, USCYL01, which activates the TFEB protein to favorably modulate tumor-associated macrophages and promote immunogenic cancer cell death, thereby...
This federal Project Grant award of $631,492 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at identifying nicotinamide N-methyltransferase (NNMT) as a new therapeutic target for treating triple-negative breast cancer (TNBC). The multi-year project, led by the University of Kentucky Research Foundation, will: Define how NNMT promotes anchorage-independent growth and protects TNBC cells from ferroptosis, a form of programmed cell death....
This $781,436 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Cold Spring Harbor Laboratory to develop anti-NMDAR antibody therapies for triple-negative breast cancer (TNBC). The key objectives are to: Establish an orthotopic mouse model of NMDAR-positive TNBC to study anti-NMDAR antibody effects. Use single-particle cryo-EM to screen anti-NMDAR antibodies and identify structural changes that could uncouple...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $442,343 will support research by the Dartmouth-Hitchcock Clinic to improve outcomes for patients with triple negative breast cancer (TNBC). The key objectives are to: Test the hypothesis that copper depletion using the drug tetrathiomolybdate (TM) can disrupt three critical aspects of TNBC metastasis - cancer cell bioenergetics, the pre-metastatic niche, and stromal...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Cancer Targeted Technology LLC to develop an innovative PSMA-targeted small molecule prodrug for the treatment of prostate cancer. The project aims to create a novel therapeutic that can deliver the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively to prostate cancer cells that overexpress the PSMA biomarker, thereby increasing the therapeutic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel therapy with dual immuno- and onco-targeting efficacies to treat triple-negative breast cancer. The $661,072 grant, awarded to Northwestern University starting January 1, 2025, will fund an IND-enabling study for a first-in-class small molecule inhibitor targeting the USP22 oncogene. This approach seeks to inhibit cancer cell growth, impair cancer stem cell properties,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding for research to evaluate the preclinical and clinical activity of DNA methyltransferase (DNMT) inhibitors in combination with standard chemoimmunotherapy for patients with triple-negative breast cancer (TNBC). The total award amount is $472,447, with a project period from December 1, 2024 to November 30, 2029. The primary grantee is Mayo Clinic, a renowned non-profit...